With reference to above subject, please find enclosed intimation regarding schedule of conference call for investors on Tuesday, November 12, 2024 at 06.30 p.m. IST to discuss the Un-audited Financial Results for the Q2 & H1FY25, to be declared on November 12, 2024.

pdf

Cohance Lifesciences Ltd.

01 Nov 2024

869.20

0.25%

Suven, Cohance aim to double combined biz revenue to Rs 6,000 cr by FY29

Business Standard

Merger-bound Suven Pharmaceuticals and Cohance Lifesciences aim to more than double their combined revenue to around Rs 6,000 crore by FY29 by undertaking both organic and inorganic growth routes, a top company official said. The entities reported a combined revenue of Rs 2,392 crore in FY24. The merged entity aims to put in place an aggressive plan to more than double revenue to Rs 6,000 crore by FY29 through both organic and inorganic growth routes, Suven Pharma Managing Director Prasada Raju said. The merger between Suven and Cohance has received approval from both NSE & BSE. As directed by National Company Law Tribunal (NCLT), the shareholders meeting of both Suven Pharmaceuticals and Cohance Lifesciences amalgamation will be held on November 28, 2024. Once finalised and approved, the combined entity will focus on three core growth drivers: pharma CDMO, specialty chemicals CDMO, and active pharmaceutical ingredients (APIs). "Together, we're building a powerhouse poised to...

Promoters have increased holdings from 50.10% to 66.41% in Jun 2025 qtr.

Cohance Lifesciences Ltd.

27 Oct 2024

869.20

0.25%

Company Update

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Publication

pdf

Cohance Lifesciences Ltd.

26 Oct 2024

869.20

0.25%

AGM

Suven Pharmaceuticals Ltd - 543064 - NCLT Convened Meeting Of Shareholders Is Scheduled To Be Held …

BSE India

NCLT Convened Meeting of shareholders is scheduled to be hled on November 28, 2024

pdf

Cohance Lifesciences Ltd.

25 Oct 2024

869.20

0.25%

Company Update

Suven Pharmaceuticals Ltd - 543064 - Update On Merger

BSE India

Update on Merger

pdf

Cohance Lifesciences Ltd.

22 Oct 2024

869.20

0.25%

Company Update

Suven Pharmaceuticals Ltd - 543064 - Update On Merger

BSE India

Update on merger

pdf

Cohance Lifesciences Ltd.

08 Oct 2024

869.20

0.25%

Company Update

Suven Pharmaceuticals Ltd - 543064 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Please find enclosed herewith the Confirmation Certificate issued by KFin Technologies Limited (RTA) for the quarter ended 30th September 2024

pdf

Cohance Lifesciences Ltd.

02 Oct 2024

869.20

0.25%

Company Update

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Mr. Brain Shaughnessy has resigned from the position of Chief Commercial Officer and Senior management Personnnel of the Company, effective on October 1, 2024

pdf

VOTE: Is Suven Pharmaceuticals Ltd. worth buying?

28 Votes:

Buy 64.29%

Sell 17.86%

Hold 17.86%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf